Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Patent: 5,622,721

« Back to Dashboard

Patent 5,622,721 protects ATELVIA and is included in one NDA. There has been one Paragraph IV challenge on Atelvia. There are four tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Summary for Patent: 5,622,721

Title: Dosage forms of risedronate
Abstract:The present invention is directed to a novel enteric-coated oral dosage form of a risedronate active ingredient comprised of a safe and effective amount of a pharmaceutical composition which is comprised of a risedronate active ingredient and pharmaceutically-acceptable excipients. Said dosage forms prohibit the exposure of the risedronate active ingredient to the epithelial and mucosal tissues of the buccal cavity, pharynx, esophagus, and stomach and thereby protects said tissues from erosion, ulceration or other like irritation. Accordingly, the said dosage forms effect the delivery to the lower gastrointestinal tract of said human or other mammal of a safe and effective amount of the risedronate active ingredient, and substantially alleviate the esophagitis or esophageal irritation which occasionally accompanies the oral administration of risedronate active ingredients.
Inventor(s): Dansereau; Richard J. (Sherburne, NY), Mosher; Russell Y. (Norwich, NY), Axelrod; Douglas W. (Norwich, NY), Sietsema; William K. (Norwich, NY)
Assignee: The Procter & Gamble Company (Cincinnati, OH)
Application Number:08/307,495
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Delivery; Formulation;
Patent PDF download available with subscription

Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Warner Chilcott Llc
ATELVIA
risedronate sodium
TABLET, DELAYED RELEASE;ORAL022560Oct 8, 2010RXYes5,622,721<disabled>YTREATMENT OF OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 5,622,721

Country Document Number Publication Date
World Intellectual Property Organization (WIPO)9309785May 27, 1993
United States of America6596710Jul 22, 2003
United States of America6096342Aug 01, 2000
United States of America5935602Aug 10, 1999
United States of America2004037884Feb 26, 2004
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: PatentStatBiotechBlogJournal of Commercial Biotechnology

`abc